Pair page
BPC-157 with Cartalax
Mechanism-tag overlap and published literature for BPC-157 and Cartalax, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
cytoprotectiontissue-repair
khavinson-cartilage-bioregulator
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying BPC-157 and Cartalax have published these mechanism-level observations. Not a co-administration recommendation.
BPC-157 has preclinical data for tendon, ligament, and joint-tissue healing through angiogenesis and growth-factor modulation. Community protocols often pair BPC-157 with Cartalax during active joint rehabilitation. Not a clinically validated combination.
Quick facts
BPC-157
Cartalax
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2025 | BPC-157 | Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PMID: 40756949. (544 articles screened, 36 studies included — the single most comprehensive systematic revie… PMID 40756949 | systematic review |
| — | BPC-157 | ClinicalTrials.gov. Study of PL 14736 in Subjects With Ulcerative Colitis. NCT05765058. | human trial |
| 2025 | BPC-157 | Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. PMID: 40131143. PMID 40131143 | human pilot |
| 2024 | BPC-157 | Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17. | human pilot |
| 2020 | BPC-157 | Xu C, Sun L, Ren F, Huang P, Tian Z, Cui J, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. (Independent safety study in mice, rats, rabbits, and dogs — no LD1 identifie… | preclinical, in vivo |
| 2006 | BPC-157 | Krivic A, Majerovic M, Jelic I, Seiwerth S, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982-989. PMID: 16583442. PMID 16583442 | preclinical, in vivo |
| 2003 | BPC-157 | Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. PMID: 14554208. PMID 14554208 | preclinical, in vivo |
| 2025 | BPC-157 | McGuire FP, Martinez R, Lenz A, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMID: 40789979. PMID 40789979 | review |
| 2025 | BPC-157 | FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025. | regulatory / registry |
| — | BPC-157 | USADA. BPC-157: Experimental Peptide Creates Risk for Athletes. U.S. Anti-Doping Agency. usada.org. | regulatory / registry |
| 2025 | BPC-157 | Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. PMID: 40005999. PMID 40005999 | research article |
| 2022 | BPC-157 | Vukojevic J, Milavic M, Perovic D, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482-487. PMID: 34380875. PMID 34380875 | research article |
| 2021 | Cartalax | Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. PMID: 34834147. PMID 34834147 | systematic review |
| 2006 | Cartalax | Gumen AV, Kozinets IA, Shanin SN, Malinin VV, Rybakina EG. Production of lymphocyte-activating factors by mouse macrophages during aging and under the effect of short peptides. Bulletin of Experimental Biology and Medicine. 2006;142(3):360-362. PMID: 17266159. PMID 17266159 | preclinical, in vivo |
| 2016 | Cartalax | Linkova NS, Drobintseva AO, Orlova OA, Kuznetsova EP, Polyakova VO, Kvetnoy IM, Khavinson VKh. Peptide regulation of skin fibroblast functions during their aging in vitro. Bulletin of Experimental Biology and Medicine. 2016;161(1):175-178. PMID: 27259486. PMID 27259486 | preclinical, in vitro |
| 2014 | Cartalax | Khavinson VKh, Tarnovskaya SI, Lin'kova NS, Polyakova VO, Durnova AO, Nichik TE, Kvetnoi IM, D'yakonov MM, Yakutseni PP. Short cell-penetrating peptides regulate fibroblast functions in cell cultures of young and old patients. Advances in Gerontology. 2014;27(4):651-656. (Key Ca… | preclinical, in vitro |
| 2011 | Cartalax | Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and the specific interaction of the peptides with deoxyribooligonucleotides and DNA in vitro. Biochemistry (Moscow). 2011;76(11):1210-1219. PM… PMID 22117548 | preclinical, in vitro |
| 2012 | Cartalax | Khavinson VKh, Solov'ev AIu, Zhilinskii DV. Molecular mechanism of the peptide regulation of gene expression: a review. Advances in Gerontology. 2012;25(3):447-456. PMID: 23289233. PMID 23289233 | mechanism / discovery |
| 2020 | Cartalax | Khavinson V, Linkova N, Diatlova A, Trofimova S. Peptide Regulation of Cell Differentiation. Stem Cell Reviews and Reports. 2020;16(1):118-125. PMID: 31813120. PMID 31813120 | bioregulator literature |
| 2016 | Cartalax | Vanyushin BF, Khavinson VKh. Short Biologically Active Peptides as Epigenetic Modulators of Gene Activity. In: Epigenetics — A Different Way of Looking at Genetics. Springer, 2016. DOI: 10.1007/978-3-319-27186-6_5. | bioregulator literature |
| 2012 | Cartalax | Khavinson VKh, Linkova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM. Peptides tissue-specifically stimulate cell differentiation during their aging. Bulletin of Experimental Biology and Medicine. 2012;153(1):148-151. PMID: 22808513. PMID 22808513 | bioregulator literature |
| 2010 | Cartalax | Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. PMID: 19633997. PMID 19633997 | bioregulator literature |
| 2005 | Cartalax | Khavinson VKh, Malinin VV. Gerontological Aspects of Genome Peptide Regulation. Karger Publishers, Basel, 2005. ISBN 3-8055-7903-3. | bioregulator literature |
| 2002 | Cartalax | Khavinson VKh. Peptides and ageing. Neuroendocrinology Letters. 2002;23(Suppl 3):11-144. PMID: 12496732. PMID 12496732 | bioregulator literature |
Related pair pages
More research context
Frequently asked
Have BPC-157 and Cartalax been studied together?
Researchers have published mechanistic-level co-administration discussion of BPC-157 and Cartalax. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do BPC-157 and Cartalax share?
BPC-157 and Cartalax do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of BPC-157 and Cartalax?
BPC-157: Category 2 (reclassification pending). Cartalax: Not approved. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on BPC-157 and Cartalax?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the BPC-157 profile and the Cartalax profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026